<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Theruvath J</submitter><funding>Children with Cancer UK</funding><funding>NCI NIH HHS</funding><funding>NINDS NIH HHS</funding><funding>The Brain Tumour Charity</funding><pagination>712-719</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7992505</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>26(5)</volume><pubmed_abstract>Atypical teratoid/rhabdoid tumors (ATRTs) typically arise in the central nervous system (CNS) of children under 3 years of age. Despite intensive multimodal therapy (surgery, chemotherapy and, if age permits, radiotherapy), median survival is 17 months&lt;sup>1,2&lt;/sup>. We show that ATRTs robustly express B7-H3/CD276 that does not result from the inactivating mutations in SMARCB1 (refs. &lt;sup>3,4&lt;/sup>), which drive oncogenesis in ATRT, but requires residual SWItch/Sucrose Non-Fermentable (SWI/SNF) activity mediated by BRG1/SMARCA4. Consistent with the embryonic origin of ATRT&lt;sup>5,6&lt;/sup>, B7-H3 is highly expressed on the prenatal, but not postnatal, brain. B7-H3.BB.z-chimeric antigen receptor (CAR) T cells administered intracerebroventricularly or intratumorally mediate potent antitumor eff</pubmed_abstract><journal>Nature medicine</journal><pubmed_title>Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors.</pubmed_title><pmcid>PMC7992505</pmcid><funding_grant_id>P30 CA124435</funding_grant_id><funding_grant_id>12-134</funding_grant_id><funding_grant_id>R25 NS065741</funding_grant_id><funding_grant_id>16/193</funding_grant_id><pubmed_authors>Mount CW</pubmed_authors><pubmed_authors>Kool M</pubmed_authors><pubmed_authors>Finetti MA</pubmed_authors><pubmed_authors>Labanieh L</pubmed_authors><pubmed_authors>Bourdeaut F</pubmed_authors><pubmed_authors>Dhingra S</pubmed_authors><pubmed_authors>Pfister S</pubmed_authors><pubmed_authors>Johann PD</pubmed_authors><pubmed_authors>Williamson D</pubmed_authors><pubmed_authors>Theruvath J</pubmed_authors><pubmed_authors>Zaidi S</pubmed_authors><pubmed_authors>Mackall CL</pubmed_authors><pubmed_authors>Sorensen PH</pubmed_authors><pubmed_authors>Xu P</pubmed_authors><pubmed_authors>Yecies DW</pubmed_authors><pubmed_authors>Delaidelli A</pubmed_authors><pubmed_authors>Majzner RG</pubmed_authors><pubmed_authors>Cheshier S</pubmed_authors><pubmed_authors>Graef CM</pubmed_authors><pubmed_authors>Puget S</pubmed_authors><pubmed_authors>Sotillo E</pubmed_authors><pubmed_authors>Heitzeneder S</pubmed_authors><pubmed_authors>Leruste A</pubmed_authors><pubmed_authors>Mitra SS</pubmed_authors><pubmed_authors>Hasselblatt M</pubmed_authors><pubmed_authors>Mueller S</pubmed_authors><pubmed_authors>Fruhwald MC</pubmed_authors><pubmed_authors>Monje M</pubmed_authors><pubmed_authors>Surdez D</pubmed_authors><pubmed_authors>Delattre O</pubmed_authors></additional><is_claimable>false</is_claimable><name>Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors.</name><description>Atypical teratoid/rhabdoid tumors (ATRTs) typically arise in the central nervous system (CNS) of children under 3 years of age. Despite intensive multimodal therapy (surgery, chemotherapy and, if age permits, radiotherapy), median survival is 17 months&lt;sup>1,2&lt;/sup>. We show that ATRTs robustly express B7-H3/CD276 that does not result from the inactivating mutations in SMARCB1 (refs. &lt;sup>3,4&lt;/sup>), which drive oncogenesis in ATRT, but requires residual SWItch/Sucrose Non-Fermentable (SWI/SNF) activity mediated by BRG1/SMARCA4. Consistent with the embryonic origin of ATRT&lt;sup>5,6&lt;/sup>, B7-H3 is highly expressed on the prenatal, but not postnatal, brain. B7-H3.BB.z-chimeric antigen receptor (CAR) T cells administered intracerebroventricularly or intratumorally mediate potent antitumor eff</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 May</publication><modification>2026-05-02T11:27:07.85Z</modification><creation>2025-04-05T17:16:28.16Z</creation></dates><accession>S-EPMC7992505</accession><cross_references><pubmed>32341579</pubmed><doi>10.1038/s41591-020-0821-8</doi></cross_references></HashMap>